Routine Comprehensive Metabolic Panel is anticipated to lead the Comprehensive Metabolic Panel CMP Testing Market at 42.0% share in 2026, followed by Routine Health Assessment as expected to secure 34.0% share of application in 2026, reflecting standardized ordering across primary care and hospital workflows. Adoption relies on reliable turnaround and reagent continuity, with calibration failure and specimen interference forming principal barriers.